Chief scientist on Operation Warp Speed resigns
The scientific adviser who guided U.S. efforts to speed up development of vaccines for Covid-19 is resigning at the behest of the incoming Biden administration.
Vaccine rollout is an administrative problem, not a distribution issue and is expected to go away
The CEOs of Pfizer, Moderna, McKesson and CVS Health explained that the distribution effort has gone well but the administration of the vaccine has now to catch up. They expect it to happen soon.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
CVS to distribute newly authorized antibody therapy
CVS Health’s infusion business will participate in a pilot to administer a recently authorized monoclonal antibody treatment to prevent patients from getting seriously ill with Covid-19. But data about the treatment, bamlanivimab, is mixed, and supply is limited.
Pfizer, BioNTech get $1.95B from HHS to supply Covid-19 vaccine
The companies will supply 100 million doses of the vaccine by the end of the year, and the government will have the option to acquire 500 million more. However, the FDA must grant an authorization based on its safety and efficacy, for which there are only preliminary data so far.
NIAID launches clinical trial network for preventive drugs, vaccines against Covid-19
The NIAID create the Covid-19 Prevention Trials Network by combining four existing ones, primarily focused on HIV and AIDS, which will continue that work in addition to their new focus on Covid-19.
Head of Trump’s Covid-19 vaccine program to divest more than $10M in Moderna shares after criticism
News media reported that Moncef Slaoui would divest his shares in Moderna, which netted him at least $3 million after the company reported promising preliminary data on its Covid-19 vaccine Monday.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.